NeuroVive Pharmaceutical AB Aktien im Umlauf

Was ist das Aktien im Umlauf von NeuroVive Pharmaceutical AB?

Aktien im Umlauf von NeuroVive Pharmaceutical AB ist 49.459M

Was ist die Definition von Aktien im Umlauf?



Im Umlauf befindliche Aktien sind alle Aktien einer Gesellschaft oder eines finanziellen Vermögenswertes, die von Anlegern genehmigt, ausgegeben und gekauft wurden und von diesen gehalten werden.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Aktien im Umlauf von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB

Was macht NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Unternehmen mit aktien im umlauf ähnlich NeuroVive Pharmaceutical AB